Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela®) in Chinese CKD Patients With Hyperphosphataemia

NCT03644264 is registered in ClinicalTrials.gov with Vifor Fresenius Medical Care Renal Pharma as lead sponsor.

NCT NCT03644264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03644264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 and Sevelamer Carbonate (Renvela®) in Chinese CKD Patients With Hyperphosphataemia
Lead sponsor
Vifor Fresenius Medical Care Renal Pharma
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2018
Completion date
August 21, 2020
Enrollment
286 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease requiring chronic dialysis, hyperphosphatemia